{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:45:30Z","timestamp":1793094330824,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["TMA2017SF-1981"],"award-info":[{"award-number":["TMA2017SF-1981"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaip.2025.05.056","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:18:36Z","timestamp":1749208716000},"page":"3336-3343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Utility of IFN-\u03b3 Enzyme-Linked Immunospot as Adjunctive Diagnostic for Severe T Cell\u2013Mediated Reactions to Cotrimoxazole in High HIV and Tuberculosis Settings"],"prefix":"10.1016","volume":"13","author":[{"given":"Rose","family":"Selim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bukiwe","family":"Thwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tafadzwa","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Sethosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tebogo","family":"Malope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Jane","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0723","authenticated-orcid":false,"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.05.056_bib1","year":"2014"},{"key":"10.1016\/j.jaip.2025.05.056_bib2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim\u2013sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.jaip.2025.05.056_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002030-200501280-00008","article-title":"Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa","volume":"19","author":"Grimwade","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2025.05.056_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jaip.2025.05.056_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.det.2013.11.004","article-title":"Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans","volume":"32","author":"Lehloenya","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2025.05.056_bib6","first-page":"1043","article-title":"Trimethoprim-sulfamethoxazole-induced drug eruption with eosinophilia and systemic symptoms (DRESS)","volume":"16","author":"Antia","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaip.2025.05.056_bib7","first-page":"S227","article-title":"Co-trimoxazole-induced DRESS syndrome: a case report","volume":"99","author":"Paitorn","year":"2016","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jaip.2025.05.056_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-203163","article-title":"A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole","volume":"2014","author":"Rijal","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2025.05.056_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1159\/000534342","article-title":"Genotypic and phenotypic characteristics of co-trimoxazole-induced cutaneous adverse reactions","volume":"239","author":"Iamsumang","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2025.05.056_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jcma.2016.01.007","article-title":"High daily doses of trimethoprim\/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS","volume":"79","author":"Chang","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jaip.2025.05.056_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-018-0778-6","article-title":"Severe cutaneous adverse drug reactions: presentation, risk factors, and management","volume":"18","author":"Mustafa","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2025.05.056_bib12","article-title":"Causes and management of cutaneous adverse drug reactions: a comprehensive review","volume":"16","author":"Sutaria","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2025.05.056_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jaip.2025.05.056_bib14","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.056_bib15","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.jaip.2024.05.045","article-title":"First-line anti-tuberculosis drug challenge reactions in DRESS in an HIV endemic setting","volume":"12","author":"Porter","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.056_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0163-4453(99)90078-6","article-title":"Desensitization to co-trimoxazole (trimethoprimsulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction?","volume":"38","author":"Gompels","year":"1999","journal-title":"J Infect"},{"key":"10.1016\/j.jaip.2025.05.056_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/jdv.13796","article-title":"Patch testing\u2013a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics","volume":"31","author":"Pinho","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.05.056_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1081-1206(10)60037-3","article-title":"Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection","volume":"76","author":"Belch\u00ed-Hern\u00e1ndez","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib19","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-\u03b3 ELISpot in severe cutaneous adverse reactions to first-line antituberculosis drugs in an HIV endemic setting","volume":"142","author":"Porter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib20","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.056_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/ijms18081737","article-title":"In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already?","volume":"18","author":"Porebski","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.05.056_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib23","doi-asserted-by":"crossref","first-page":"1000.e2","DOI":"10.1016\/j.jaad.2013.11.053","article-title":"Comments on: DRESS syndrome","volume":"71","author":"Kardaun","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib26","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.05.056_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.05.056_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.05.056_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","article-title":"Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.05.056_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/icb.2011.34","article-title":"High-avidity, high-IFN\u03b3-producing CD8 T-cell responses following immune selection during HIV-1 infection","volume":"90","author":"Keane","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaip.2025.05.056_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.184","article-title":"Visualizing set relationships: EVenn's comprehensive approach to Venn diagrams","volume":"3","author":"Yang","year":"2024","journal-title":"iMeta"},{"key":"10.1016\/j.jaip.2025.05.056_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.573573","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2025.05.056_bib34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QCO.0000000000000323","article-title":"Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity","volume":"29","author":"Konvinse","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jaip.2025.05.056_bib35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/QAD.0000000000000345","article-title":"HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity","volume":"28","author":"Keane","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2025.05.056_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/187152812800392751","article-title":"Detection of abacavir hypersensitivity by ELISpot method","volume":"11","author":"Esser","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jaip.2025.05.056_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2017.09.004","article-title":"The combined utility of ex vivo IFN-\u03b3 release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions","volume":"6","author":"Trubiano","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.056_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2022.09.011","article-title":"Utility and safety of skin tests in drug reaction with eosinophilia and systemic symptoms (DRESS): a systematic review","volume":"11","author":"Teo","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.056_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cod.14692","article-title":"Patch testing in non-immediate hypersensitivity to cotrimoxazole: is it useful?","volume":"91","author":"Soares","year":"2024","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.05.056_bib40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jnci\/51.3.1075","article-title":"Quantitative impairment of primary inflammatory response in patients with cancer","volume":"51","author":"Johnson","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaip.2025.05.056_bib41","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.4049\/jimmunol.164.12.6647","article-title":"Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals","volume":"164","author":"Schnyder","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjp.0703845","article-title":"Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells","volume":"132","author":"Burkhart","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaip.2025.05.056_bib43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ACI.0000000000000545","article-title":"Drug hypersensitivity in HIV infection","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2249.2007.03477.x","article-title":"Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease","volume":"150","author":"Clark","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib45","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/01.aids.0000191923.08938.5b","article-title":"Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count","volume":"19","author":"Dheda","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2025.05.056_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40413-016-0122-3","article-title":"Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement","volume":"9","author":"Kowalski","year":"2016","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.05.056_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacig.2021.11.001","article-title":"Blister fluid as a cellular input for ex vivo diagnostics in drug-induced severe cutaneous adverse reactions improves sensitivity and explores immunopathogenesis","volume":"1","author":"Awad","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2025.05.056_bib49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ACI.0b013e328348a4e9","article-title":"Drug provocation tests in hypersensitivity drug reactions","volume":"11","author":"Rerkpattanapipat","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.056_bib50","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.056_bib51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev-pharmtox-010818-021818","article-title":"Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions","volume":"59","author":"Karnes","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaip.2025.05.056_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.101002","article-title":"Exploring cytokine outputs for ex vivo diagnostics in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"17","author":"Copaescu","year":"2024","journal-title":"World Allergy Organ J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:08:18Z","timestamp":1778893698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825005331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2213219825005331"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.056","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of IFN-\u03b3 Enzyme-Linked Immunospot as Adjunctive Diagnostic for Severe T Cell\u2013Mediated Reactions to Cotrimoxazole in High HIV and Tuberculosis Settings","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}